[{"address1": "100 Overlook Center", "address2": "Suite 102", "city": "Princeton", "state": "NJ", "zip": "08540", "country": "United States", "phone": "609 375 2227", "website": "https://www.sonnetbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Dr. Pankaj  Mohan Ph.D.", "age": 58, "title": "Founder, Chairman, CEO & President", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 538998, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John K. Cini Ph.D.", "age": 70, "title": "Chief Scientific Officer & Co-Founder", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 397750, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jay  Cross", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 389953, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Donald J. Griffith CPA, CPA", "age": 74, "title": "Financial Controller & Director", "yearBorn": 1949, "fiscalYear": 2024, "totalPay": 90256, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gael  Hedou Ph.D.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan  Dexter", "age": 68, "title": "Chief Technical Officer", "yearBorn": 1955, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard T. Kenney FACP, M.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Manuel  Dafonseca", "title": "Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 3.69, "open": 3.63, "dayLow": 3.2, "dayHigh": 3.63, "regularMarketPreviousClose": 3.69, "regularMarketOpen": 3.63, "regularMarketDayLow": 3.2, "regularMarketDayHigh": 3.63, "beta": 1.045, "forwardPE": -0.22259358, "volume": 191856, "regularMarketVolume": 191856, "averageVolume": 433609, "averageVolume10days": 2603300, "averageDailyVolume10Day": 2603300, "bid": 3.39, "bidSize": 100, "marketCap": 2273254, "fiftyTwoWeekLow": 3.03, "fiftyTwoWeekHigh": 18.72, "priceToSalesTrailing12Months": 40.680267, "fiftyDayAverage": 5.7852, "twoHundredDayAverage": 10.1919, "currency": "USD", "enterpriseValue": -1130890, "floatShares": 585988, "sharesOutstanding": 682659, "sharesShort": 20844, "sharesShortPriorMonth": 4342, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0321, "heldPercentInsiders": 0.04222, "heldPercentInstitutions": 0.10845, "shortRatio": 0.68, "shortPercentOfFloat": 0.0326, "bookValue": 4.014, "priceToBook": 0.8295964, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -7985378, "trailingEps": -0.96, "forwardEps": -14.96, "lastSplitFactor": "1:26", "lastSplitDate": 1585785600, "enterpriseToRevenue": -20.237, "enterpriseToEbitda": 0.092, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SONN", "underlyingSymbol": "SONN", "shortName": "Sonnet BioTherapeutics Holdings", "longName": "Sonnet BioTherapeutics Holdings, Inc.", "firstTradeDateEpochUtc": 1162305000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e0f4f091-b896-3bb3-bb50-c62febf22cab", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.33, "targetHighPrice": 240.0, "targetLowPrice": 56.0, "targetMeanPrice": 148.0, "targetMedianPrice": 148.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 3554331, "totalCashPerShare": 5.207, "ebitda": -12263398, "totalDebt": 150186, "quickRatio": 1.31, "currentRatio": 1.649, "totalRevenue": 55881, "debtToEquity": 5.736, "revenuePerShare": 0.019, "returnOnAssets": -0.96928, "returnOnEquity": -2.64567, "freeCashflow": -9881685, "operatingCashflow": -9996666, "operatingMargins": -219.68546, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-11"}]